Replies to post #411754 on Anavex Life Sciences Corp (AVXL)

[Investor2014]

I think with the following edits the Anavex statement would have been closer to the actual situation.

ANAVEX®2-73 (BLARCAMESINE) PHASE 2B/3 STUDY MET PRIMARY AND KEY SECONDARY ENDPOINTS, SHOWING STATISTICALLY SIGNIFICANT REDUCTION OF CLINICAL DECLINE IN GLOBAL CLINICAL STUDY OF PATIENTS WITH EARLY ALZHEIMER’S DISEASE

- Robust, Statistically Significant and Clinically Meaningful Absolute Improvement in Cognitive Function as Measured by ADAS-Cog and ADCS-ADL in a certain subgroup of patients as expressed by Odds Ratios

They have worded it as an omission (made by a tired forgetful employee or better still 3rd party CRO), rather than a deliberate misstatement.

[tredenwater2]

Yes abew, Dr. Missling and (growing) company continue to assert meeting both endpoints in our Alzheimer’s trial. Who would know better whether we met those or not than the newest edition(s) to the team. As cautious and conservative as Dr. Missling has been historically with attracting lawsuits he has either grown completely crazy, or he telling the truth. There is no way the new guys/gal would accept lead positions respectively on the BOD and VP if data were skewed/sketchy.

Many only see black and white through traditional “lenses” but the Anavex picture is coming quickly into color.

2023!

OAN, is it me or is Dr. Missling seem like he is shifting into 4rth gear comfortably cruising into approval. World wide market penetrations with most excellent patent protection, hiring, filing